Clinical Trials
11 trialsNCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT05085977 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT05085990 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT03191578 2023-07-14
RUTIVAC-1
Archivel Farma S.L.
Phase 1 Completed
NCT03854721 2023-03-03
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer
Vaxiion Therapeutics
Phase 1 Completed
NCT02316171 2022-07-27
CANON
Viralytics
Phase 1 Completed
NCT03053635 2018-08-20
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
TheralaseĀ® Technologies Inc.
Phase 1 Completed
NCT02852564 2017-08-22
Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection
University of Kansas Medical Center
Phase 1 Completed
NCT01498172 2015-02-04
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
University of Lausanne Hospitals
Phase 1 Completed
NCT01458847 2012-11-12
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
BioCis Pharma Ltd
Phase 1 Completed
NCT00782587 2010-02-08
IPOP
Halozyme Therapeutics
Phase 1 Completed